New weekly shot shows promise for obesity – but It's early days

NCT ID NCT06857617

Completed Disease control Sponsor: Metsera, a wholly owned subsidiary of Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called MET097, given as a weekly injection, to see if it is safe and helps with weight loss in adults who are overweight or obese but otherwise healthy. About 120 participants will receive either MET097 or a placebo for up to 12 weeks, with some exploring a once-monthly dose. The goal is to measure weight change and how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MET097 (a biologic injection)
What this could lead to: If successful, this could lead to a new once-weekly or even once-monthly injection to help people with obesity lose weight.
What could go wrong: This is an early Phase 1/2 trial with only 120 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY AND OVERWEIGHT

Contacts and locations

Locations

Research Site MET097 23-101-001

Overland Park, Kansas, 66212, United States
Research Site MET097 23-101-002

Anaheim, California, 92801, United States
Research Site MET097 23-101-003

Cypress, California, 90630, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.